The dialyzability of iohexol was examined in patients with chronic renal failure on long-term hemodialysis treatment. Eight patients had iohexol (Omnipaque® 240 or 350 mg I/ml) injected in doses between 98 and 1,493 mg I/kg body weight (BW) 25 h (mean time) before start of hemodialysis. Dialysance of iohexol was 81 ± 15 ml/min (mean ± SD) compared to 120 ± 16.8 ml/min for creatinine. Elimination half-life for iohexol during hemodialysis was 3.9 ± 1.1 h while plasma clearance was 64 ± 17 ml/min. The distribution volume calculated (0.25 ± 0.05 liters/kg BW) confirms previous observations with distribution in the extracellular fluid only. Before the start of hemodialysis 36 ± 28% of the dose injected was eliminated, indicating some extrarenal elimination. After 4 h of hemodialysis 72 ± 11% of the dose was removed.

No abstract

Renal effects of the new non-ionic contrast medium iopentol in increasing doses were assessed and compared with the effects of physiologic saline. Twenty-four healthy male volunteers, allocated to three dose groups, were given iopentol intravenously in doses of 0.3, 0.6, and 1.2 g I/kg body weight, respectively. The highest dose group was also given physiologic saline separately as a control. The diuresis increased in all groups, most in the highest dose group, and with a concomitant fall of urine osmolality and increase in osmolar clearance. A slight decrease of serum osmolality, creatinine and urea occurred at 3 hours due to hemodilution. The glomerular filtration rate was unaffected by iopentol. The urinary excretion of albumin and β2-microglobulin was unchanged. However, urinary N-acetyl-β-glucosaminidase and alkaline phosphatase increased significantly, most in the highest dose group. All changes were reversible.

No abstract

Conventional contrast echo techniques have proved inadequate for the detection of myocardial perfusion using intravenously injected echo contrast agents because of the limitations and relative insensitivity of standard echocardiographic equipment. In order to avoid these problems, we have obtained pure digital radiofrequency ultrasound data from the left ventricle and myocardium during i.v. contrast myocardial perfusion echo studies. In 30 patients, following coronary arteriography, i.v. injections of the echo contrast agent Albunex (sonicated human serum albumin) in two doses of 0.08 and 0.22 ml.kg-1 were administered during digital radiofrequency echocardiography sampling of data from the myocardium and left ventricular cavity. Analysis of mean integrated backscatter (MIB, a measure of the total ultrasound energy) was performed before, during and after Albunex injection. The data were also analysed for a shift in frequency spectrum which could be caused by resonance of the Albunex contrast microspheres in the heart, a phenomenon which has been previously demonstrated in vitro. Digital radiofrequency ultrasound data were successfully obtained and analysed in 23 patients. In 31 segments where reasonable resting perfusion was expected, there was a significant increase in MIB from 0.644 to 1.245, P < 0.001 and time intensity curves could be constructed showing wash-in and wash-out of contrast from the myocardium. In 10 segments supplied by significantly diseased vessels, MIB intensity increased from 1.044 to 1.874, P = 0.054. In myocardial segments supplied by non-diseased vessels, microsphere resonance also caused a drop in mean frequency of 140 KHz, P < 0.001, and permitted similar temporal analysis of myocardial perfusion.(ABSTRACT TRUNCATED AT 250 WORDS)